| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Business Officer
2 companies
Jeremy P. Springhorn is Director at QURE and has filed Form 4s across 2 companies. From December 2017 to June 2026, the filings on record show 2 open-market purchases and 9 sales. Jeremy P. Springhorn's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.0M at current prices.
Historically, Jeremy P. Springhorn's trades have earned a below-average insider score of 46/100 across 6 rated trades. Over a 12-month horizon, 40.0% of those trades were profitable, with an average 12-month return of -16.1%.
The biggest single holding is QURE (~$1.0M) as Director. The QURE filings lean toward selling, a net 12,130 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2017 | SYRS Syros Pharmaceuticals, Inc. | Chief Business Officer | Buy | 15,000 | $9.08 | $136,260.00 | New |